Bone Biologics regains compliance with Nasdaq listing
Regaining Compliance: Bone Biologics has received confirmation from The Nasdaq Stock Market that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Continued Listing: The company is now compliant with all applicable listing standards, ensuring its common stock will remain listed on the Nasdaq Capital Market.
Trade with 70% Backtested Accuracy
Analyst Views on BBLG
About BBLG
About the author
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Product Shelf Life Extension: Bone Biologics successfully extended the shelf life of its rhNELL-1 protein product to 24 months, which not only enhances manufacturing efficiency but also improves supply chain flexibility, supporting clinical readiness.
- Strengthened Capital Structure: The company completed a $5 million registered public offering in Q2 2025, providing funding to support ongoing clinical development activities and intellectual property initiatives, ensuring stability in capital markets.
- Intellectual Property Expansion: Bone Biologics filed a U.S. patent application related to its bone regeneration technology, further strengthening its proprietary platform and enhancing long-term value in the competitive landscape.
- Nasdaq Compliance Restored: The company regained compliance with Nasdaq's minimum bid price requirement in June 2025, reinforcing its ability to access public capital markets continuously.
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Shelf Life Extension: Bone Biologics announces that the shelf life of its rhNELL-1 product has been extended to 24 months, based on ongoing stability data, representing a logical progression from prior 12- and 18-month milestones.
- Manufacturing Efficiency Improvement: The extended shelf life is expected to enhance manufacturing efficiency, inventory management, and supply chain flexibility, thereby supporting clinical and commercial readiness as the company advances product development.
- Accelerated Commercialization: CEO Jeff Frelick states that this milestone is an important step toward commercialization, expected to support disciplined capital deployment and long-term shareholder value creation.
- Bone Regeneration Technology Development: Bone Biologics is developing rhNELL-1 as a differentiated bone growth factor designed to promote bone regeneration in hard-to-heal fusion settings, further solidifying its competitive position in the spinal fusion market.
Bone Biologics Announces Closing of $5.0 Million Public Offering
Public Offering Announcement: Bone Biologics Corporation has completed a public offering of 1,250,000 shares of common stock and accompanying warrants, raising $5 million in gross proceeds, with potential additional proceeds of $10 million from warrant exercises.
Use of Proceeds: The company plans to use the net proceeds for funding clinical trials, maintaining its patent portfolio, and general corporate purposes, while also focusing on regenerative medicine for bone and spinal fusion procedures.
Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket
Venus Concept Inc. Stock Surge: Shares of Venus Concept Inc. rose 32.5% to $2.91 in pre-market trading after Madryn Asset Management increased its stake in the company to 85.5%.
Pre-Market Trading Highlights: Other notable stock movements include Professional Diversity Network surging 233.7%, while INmune Bio saw a significant drop of 46.7% following trial results.
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
Market Update: The trading week is nearing its end, but there are still significant stock market stories to follow.
TipRanks Resource: Investors can find the top headlines and hottest stock market news on TipRanks today.
Bone Biologics Prices $5 Mln Public Offering With Warrants At $4 Per Share
Public Offering Details: Bone Biologics Corporation has announced a public offering of 1,250,000 shares of common stock along with Series D and E warrants, aiming for gross proceeds of $5.0 million, potentially increasing to $15.0 million if all warrants are exercised.
Use of Funds and Market Performance: The funds will be allocated for clinical trials, IP expansion, and general corporate purposes, while the company's stock is currently trading at $4.84, reflecting a 16.35% increase on NasdaqCM.
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Product Shelf Life Extension: Bone Biologics successfully extended the shelf life of its rhNELL-1 protein product to 24 months, which not only enhances manufacturing efficiency but also improves supply chain flexibility, supporting clinical readiness.
- Strengthened Capital Structure: The company completed a $5 million registered public offering in Q2 2025, providing funding to support ongoing clinical development activities and intellectual property initiatives, ensuring stability in capital markets.
- Intellectual Property Expansion: Bone Biologics filed a U.S. patent application related to its bone regeneration technology, further strengthening its proprietary platform and enhancing long-term value in the competitive landscape.
- Nasdaq Compliance Restored: The company regained compliance with Nasdaq's minimum bid price requirement in June 2025, reinforcing its ability to access public capital markets continuously.
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Shelf Life Extension: Bone Biologics announces that the shelf life of its rhNELL-1 product has been extended to 24 months, based on ongoing stability data, representing a logical progression from prior 12- and 18-month milestones.
- Manufacturing Efficiency Improvement: The extended shelf life is expected to enhance manufacturing efficiency, inventory management, and supply chain flexibility, thereby supporting clinical and commercial readiness as the company advances product development.
- Accelerated Commercialization: CEO Jeff Frelick states that this milestone is an important step toward commercialization, expected to support disciplined capital deployment and long-term shareholder value creation.
- Bone Regeneration Technology Development: Bone Biologics is developing rhNELL-1 as a differentiated bone growth factor designed to promote bone regeneration in hard-to-heal fusion settings, further solidifying its competitive position in the spinal fusion market.
Bone Biologics Announces Closing of $5.0 Million Public Offering
Public Offering Announcement: Bone Biologics Corporation has completed a public offering of 1,250,000 shares of common stock and accompanying warrants, raising $5 million in gross proceeds, with potential additional proceeds of $10 million from warrant exercises.
Use of Proceeds: The company plans to use the net proceeds for funding clinical trials, maintaining its patent portfolio, and general corporate purposes, while also focusing on regenerative medicine for bone and spinal fusion procedures.
Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket
Venus Concept Inc. Stock Surge: Shares of Venus Concept Inc. rose 32.5% to $2.91 in pre-market trading after Madryn Asset Management increased its stake in the company to 85.5%.
Pre-Market Trading Highlights: Other notable stock movements include Professional Diversity Network surging 233.7%, while INmune Bio saw a significant drop of 46.7% following trial results.
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
Market Update: The trading week is nearing its end, but there are still significant stock market stories to follow.
TipRanks Resource: Investors can find the top headlines and hottest stock market news on TipRanks today.
Bone Biologics Prices $5 Mln Public Offering With Warrants At $4 Per Share
Public Offering Details: Bone Biologics Corporation has announced a public offering of 1,250,000 shares of common stock along with Series D and E warrants, aiming for gross proceeds of $5.0 million, potentially increasing to $15.0 million if all warrants are exercised.
Use of Funds and Market Performance: The funds will be allocated for clinical trials, IP expansion, and general corporate purposes, while the company's stock is currently trading at $4.84, reflecting a 16.35% increase on NasdaqCM.
